Zhou Yimin, Liu Xiangdong, Gao Wei, Luo Xin, Lv Junying, Wang Yunshan, Liu Duanrui
School of Basic Medical Sciences, Shandong University, Jinan 250011, China.
Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China.
Heliyon. 2023 Dec 20;10(1):e23919. doi: 10.1016/j.heliyon.2023.e23919. eCollection 2024 Jan 15.
Immunotherapy, specifically immune checkpoint inhibitors, has emerged as a promising approach for treating malignant tumors. The gut, housing approximately 70 % of the body's immune cells, is abundantly populated with gut bacteria that actively interact with the host's immune system. Different bacterial species within the intestinal flora are in a delicate equilibrium and mutually regulate each other. However, when this balance is disrupted, pathogenic microorganisms can dominate, adversely affecting the host's metabolism and immunity, ultimately promoting the development of disease. Emerging researches highlight the potential of interventions such as fecal microflora transplantation (FMT) to improve antitumor immune response and reduce the toxicity of immunotherapy. These remarkable findings suggest the major role of intestinal flora in the development of cancer immunotherapy and led us to the hypothesis that intestinal flora transplantation may be a new breakthrough in modifying immunotherapy side effects.
免疫疗法，特别是免疫检查点抑制剂，已成为治疗恶性肿瘤的一种有前景的方法。肠道容纳了人体约70%的免疫细胞，肠道中大量存在着与宿主免疫系统积极相互作用的肠道细菌。肠道菌群中的不同细菌种类处于微妙的平衡状态并相互调节。然而，当这种平衡被打破时，致病微生物可能占据主导地位，对宿主的代谢和免疫产生不利影响，最终促进疾病的发展。新出现的研究强调了诸如粪便微生物群移植（FMT）等干预措施在改善抗肿瘤免疫反应和降低免疫疗法毒性方面的潜力。这些显著发现表明肠道菌群在癌症免疫疗法发展中的重要作用，并使我们提出这样的假设：肠道菌群移植可能是改善免疫疗法副作用的一个新突破。
